<DOC>
	<DOC>NCT02787824</DOC>
	<brief_summary>The purpose of this study was to compare the efficacy of two regimens of intravenous iron sucrose [continuous (in every hemodialysis session) versus intermittent (every 1-4 weeks)] on the response of rHuEPO in the maintenance phase of its administration in hemodialysis patients.</brief_summary>
	<brief_title>Periodic Versus Continuous IV Iron Supplementation in HD Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide, saccharated</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Constant rHuEPO and iron dose for at least 2 months before starting the study Hemoglobin â‰¥ 8,5g/dl and &lt;12,5 g/dl Ferritin &lt; 1000 mg/dl TSAT &lt; 50% CRP &lt; 5 mg/dl Malignant tumor disease Oral iron supplementation Active bleeding issues Surgical intervention within the last 8 weeks before study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>iron deficiency</keyword>
	<keyword>hemodialysis</keyword>
</DOC>